Introduction
============

Ovarian cancer was ranked as one of the prevalently lethal gynecologic malignancies, and it was estimated that there is a global incidence of 22,440 new cases per year, with an incidence of 14,080 deaths annually.[@b1-cmar-10-3433] Currently, the standard treatment for ovarian cancer consists of cytoreductive surgery and adjuvant chemotherapy.[@b2-cmar-10-3433] Recent studies have examined platinum-containing chemotherapeutic drugs and targeted therapy, like poly(ADP-ribose) polymerase inhibitors, niraparib, veliparib, and rucaparib. Despite the advancement of new treatment agents, it remains the highest in mortality rate of all gynecological malignancies.[@b3-cmar-10-3433] Moreover, lack of early diagnosis and the appearance of tumor metastasis and drug resistance resulted in barely 20%--40% 5-year survival rate in ovarian cancer patients.[@b4-cmar-10-3433] Most patients are not detected until they progress into advanced stage, ie, International Federation of Gynecology and Obstetrics stage (FIGO) stages III or IV.[@b5-cmar-10-3433] Consequently, there is urgent need to discover new biomarkers. Presently, many serum markers of ovarian cancer, such as CA125, CA199, and CA153, have been used in the clinic for predicting metastasis and prognosis.[@b5-cmar-10-3433],[@b6-cmar-10-3433] Moreover, ETV5, ALX1, and GOLPH3L have been confirmed as potential prognostic and progressive markers in ovarian cancer.[@b7-cmar-10-3433]--[@b9-cmar-10-3433] Nevertheless, these indicators are neither remarkably sensitive nor specific for predicting tumor recurrence and progression. Therefore, novel biomarkers that contribute to detect metastasis and chemoresistance and predict tumor progression for patients with ovarian cancer are needed.

KIF20A was localized to the Golgi apparatus and consisted of 890--amino acid. KIF20A, a microtubule-associated motor protein, functions in mitosis, migration, and intracellular transport.[@b10-cmar-10-3433] Importantly, recent studies have shown that KIF20A is a significant downstream target gene of Hedgehog (Hh) signaling, which was related to cancer cell proliferation, invasion, metastasis, and autophagy. In addition, glioma-associated oncogene 2 (GLI2), a principal transcriptional regulator of Hh signaling, combines with KIF20A to form the GLI2--KIF20A axis, which is necessary for the proliferation and progression of human hepatocellular carcinoma cells.[@b11-cmar-10-3433] Some studies have demonstrated a correlation between KIF20A and human cancer of several different organs, involving bladder cancer, breast cancer, gastric cancer, melanoma, and hepatocellular carcinoma.[@b11-cmar-10-3433]--[@b15-cmar-10-3433] However, the patterns of KIF20A expression and its clinical significance have not been investigated in epithelial ovarian cancer (EOC). Herein, the goal of our research was to explore the clinical significance of KIF20A expression in EOC.

Materials and methods
=====================

Cell lines
----------

The human ovarian cancer cell lines (COV644, COV362, OV90, SKOV3, TOV112D, OVCAR4, A2780, and COV434, TOV21G) and normal ovarian epithelial cells (HOSEpiC) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). HOSEpiC were cultured in Defined Keratinocyte-SFM (1×) (Invitrogen, Carlsbad, CA, USA). The ovarian cancer cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10% fetal bovine serum (Gibco, Grand-Island, NY, USA) and 1% penicillin (100 U/mL) and streptomycin (100 µg/mL) at 37°C under 5% CO~2~ incubator added.

Tissue specimens and patient information
----------------------------------------

This research was carried out on the paraffin-embedded tissues from 150 EOC patients and 10 freshly paired EOC tissues, which were diagnosed at Sun Yat-sen University Cancer Center between 2001 and 2010. The clinical characteristics of the 150 samples are recorded in [Table 1](#t1-cmar-10-3433){ref-type="table"}. The median follow-up time for the whole samples was 49.83 months (range from 3 to 178.2 months). The approval from Sun Yat-sen University Cancer Center Institutional Review Ethics Board was obtained (YB2017-037). Written informed consent was obtained from each patient, and the experiments involving human tissue samples were approved by the Institutional Review Ethics Board of Sun Yat-sen University Cancer Center.

Plasmids, infection, and transfection
-------------------------------------

Human KIF20A complementary DNA (cDNA) was polymerase chain reaction (PCR)-amplified by PCR forward: agatctGCCACCATGTCGCAAGGGATCCTTTC; reverse: gaattcTTAGTACTTTTTGCCAAAAG. To silence KIF20A, two siRNAs against KIF20A in pSuper-puro vector were obtained from Ribobio Inc (Guangzhou, Guangdong, China). The siRNA sequences are as follows: si-KIF20A-1 :5′-CTCCGAGATGAAATTTGCA-3′; si-KIF20A-2 :5′-GGTCTGTGGTACGCAAGAA-3′; Transfection was performed using Lipofectamine 3000 reagent (Invitrogen) in line with the manufacturer's instructions.

RNA extraction reverse transcription and real-time PCR
------------------------------------------------------

Total RNA was isolated from 10 freshly paired clinical samples and cell lines by using Trizol reagent (Invitrogen) based on the manufacturer's instructions. Then, we used RNase-free DNase to inhibit degradation. In line with the manufacturer's guidelines, we used Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) to synthesize cDNA from RNA (2 µg) obtained from each sample. The qPCR primer sequences were displayed as follows: KIF20A forward primer: 5′-TCAGAGCGCTGCAAAGATCA-3′; KIF20A reverse primer: 5′-CGGTTCTGCTGGTTTTGACG-3′; GAPDH forward primer: 5′-AGAGGCAGGGATGATGTTCTG-3′; and GAPDH reverse primer; 5′-AGAGGCAGGGATGATGTTCTG-3′. We used the 2−ΔΔCt method to detect relative quantitative value, where Ct represents the threshold cycle for each transcript. All experiments were tested in triplicate.

Western blotting
----------------

Total protein was obtained from frozen tissues and cultured cells by using a Whole Protein Extraction Kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Western blots analysis was practiced on the basis of standard steps. Briefly, we used ice-cold PBS to wash cells thrice, and then lysed it on ice in 1× SDS lysis buffer with protease inhibitors. Liquid nitrogen was added to fresh clinic tissue samples, and then we grinded it to powder and used sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer to lyse it. Protein concentrations were determined by the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal quantities of protein (30 µg) were resolved on 9% SDS polyacrylamide gels, electrotransferred to polyvinylidene fluoride (PVDF) membranes (Immobilon P; Millipore, Bedford, MA, USA). The membranes was immunoblotted with primary antibody against KIF20A (1:200; Sigma-Aldrich, St. Louis, MO, USA; HPA036910) and GAPDH (1:5,000; Sigma-Aldrich, SAB2701826) at 4°C overnight, after the membranes were blocked in 5% skimmed milk for 1 hour. Then, we washed the membranes thrice with Tris-buffered saline/0.1% Tween 20 (TBST) for 10 minutes each time, followed by the secondary antibody (1:3000, anti-rabbit antibody, Abcam, Cambridge, MA, USA, ab6721) for 2 hours at room temperature. Finally, the bound antibodies were visualized by chemiluminescence detection reagent (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in line with the manufacturer's guideline. Anti-GAPDH antibody was used as a loading control.

Immunohistochemistry
--------------------

Immunohistochemistry (IHC) analysis was performed to detect KIF20A protein expression in 150 EOC patients. Briefly, all specimens were cut into 4-µm sections and baked at 60°C for 1 hour. We removed paraffin from these sections by using xylene, once in 10 minutes, twice. Then, these sections were treated in different ethanol solutions (100%, 100%, 95%, 90%, and 80%). Then, EDTA antigenic retrieval buffer and microwave were used to retrieve antigenic of the sections. In order to extinguish endogenous peroxidase activity, the samples were processed with 3% hydrogen peroxide in methanol. Then, 1% bovine serum albumin was selected to block nonspecific blinding. Subsequently, rabbit polyclonal anti-KIF20A antibody (1:600; Sigma; HPA036910) was used to incubate the sections overnight at 4°C. PBS served as the negative control. After washing, the clinical sections were processed with prediluted anti-rabbit secondary antibody (Abcam), followed by treatment with streptavidin--horseradish peroxidase complex (Sigma), and then soaked in 3-amino-9-ethylcarbazole. These sections were mounted in Crystal Mount after the processing of counterstaining with 10% Mayer's hematoxylin and dehydrating. The score of immunostaining was separately evaluated by two pathologists who were blinded to the clinical parameters. Evaluation of KIF20A protein expression and scores of immunostaining were assessed by two observers separately. The staining intensity of KIF20A was classified as follows: 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining). The proportion of tumor cells was graded from 0 to 3: 0 (\<10%), 1 (10%--50%), 2 (51%--75%), and 3 (\>75%). The product of the proportion of tumor cells and staining intensity score was seen as the staining index. According to the methods of this evaluation, we assessed KIF20A expression in ovarian cancer samples by determining the staining intensity (SI), with scores of 0--9. The median SI of all ovarian cancer tissues was 4. Thus, we distinguished high and low KIF20A expressions by the following criteria: SI ≤4 was defined as tumors with low KIF20A expression; SI ≥6 was indicated as tumors with high KIF20A expression.

Transwell assay
---------------

Transwell chambers (8-µm pore size, Corning Inc., Corning, NY, USA) coated with Matrigel (BD Biosciences, San Jose, CA, USA) were used to assess the ability of migration and invasion. Briefly, ovarian cancer cells (2×10^4^) were incubated in serum-free medium and then added to the upper chamber of transwell chambers. The lower chamber was added with 10% FBS culture medium. After incubation at 37°C for 24 hours, the cells in the upper chamber were transited into the lower surface. We used 4% paraformaldehyde and stained it with hematoxylin. Finally, we used microscope (Nikon Eclipse 80i) to count the cells (10 random 200 × fields per well). All experiments were conducted three times.

Wound healing assay
-------------------

The ovarian cancer cells transfected vector KIF20A or KIF20A siRNA were seeded in six-well plates and grown until almost confluence in 24 hours, and then cultured in serum-free medium for 24 hours. We used a 200-µL pipette to scratch an artificial homogeneous wound of cell monolayers, followed by washing with PBS and cultured it in DMEM plus 10% FBS. Inverted microscope was used to measure the average distance between the edge and the center of the straight scratch at time points 0, 12, and 24 hours (with a 10× objective lens).

MTT assays
----------

The sensitivity to cisplatin of EOC cells was measured using MTT assays followed by the manufacturer's instructions. Briefly, 4×10^3^ cells were put on 96-well plates and cultured at 37°C overnight and treated with different cisplatin concentrations (3, 9, 27, 81, and 243 µm) for 48 hours. We added the MTT solution (20 µL; 5 mg/mL), and the plates were further incubated for 4 hours. At the end point, 200 µL DMSO was added to the plates in order to stabilize the product. The absorbance was measured at 570 nm. The IC50 values were analyzed using the GraphPad Prism^®^ six software.

Annexin V/PI assay
------------------

Annexin V Apoptosis Detection Kit (Beyotime) was used to assess apoptosis following the instructions. Briefly, ovarian cancer cells (2×10^5^) were seeded in six-well plates, then treated with cisplatin (5 µM) for 24 hours, and FITC Annexin V and propidium iodide (each at 5 µL/10^5^ cells) were added. After these processes, we incubated cells at room temperature without light for 15 minutes. We used flow cytometer (Beckman Coulter, Brea, CA, USA) to analyze the flow cytometry data.

Statistical analysis
--------------------

We used the SPSS 20.0 (SPSS Inc., Chicago, IL, USA) to carry out statistical analyses. Chi-squared test and Fisher's exact test were used to analyze the correlation of KIF20A protein and clinicopathological features. Spearman's rank correlation coefficients were utilized to assess the bivariate association between the clinical variables. The Kaplan--Meier method and log-rank testing were carried out to plot survival curves of EOC patients with high or low KIF20A expression. Furthermore, the Cox regression model was applied to calculate the relative risk ratios and analyze the survival data. In all experiments, *P*\<0.05 was regarded to be statistically significant.

Results
=======

KIF20A expression was upregulated in ovarian cancer cell lines
--------------------------------------------------------------

To explore KIF20A expression in ovarian cancer, we detected KIF20A expression in different kinds of ovarian cancer cells (COV644, COV362, OV90, SKOV3, TOV112D, OVCAR4, A2780, COV434) and HOSEpiC at mRNA and protein levels. The results showed that KIF20A was elevated in all of the ovarian cancer cell lines compared with HOSEpiC (*P*\<0.05; [Figure 1A, B](#f1-cmar-10-3433){ref-type="fig"}).

KIF20A expression in EOC and normal control tissues
---------------------------------------------------

The KIF20A expression of 10 paired fresh EOC tissues and the adjacent noncancerous tissues was examined at transcription and translation levels. As shown in [Figure 2A--C](#f2-cmar-10-3433){ref-type="fig"}, KIF20A expression was significantly upregulated in 10 ovarian cancer tissues compared with the paired noncancerous tissues (*P*\<0.05). Next, we carried out IHC staining to detect the KIF20A protein expression level ([Figure 2D](#f2-cmar-10-3433){ref-type="fig"} and [Figure S1A](#SD1-cmar-10-3433){ref-type="supplementary-material"}). The results were strongly consistent with the KIF20A protein expression examined by Western blotting.

Association between KIF20A upregulation and EOC clinical features
-----------------------------------------------------------------

IHC analysis was carried out on 150 EOC samples to assess the value of KIF20A protein upregulation in EOC and then to analyze the correlation between KIF20A expression and the clinicopathological variables. The relationship between KIF20A protein level expression in EOC patients and the clinicopathological variables is presented in [Tables 2](#t2-cmar-10-3433){ref-type="table"} and [3](#t3-cmar-10-3433){ref-type="table"}. The 150 clinic samples contained 25 stage I cases, 18 stage II cases, 83 stage III cases, and 9 stage IV cases (15 medical records did not have detailed clinical staging information). Of the 150 samples, 90 cases (60%) had a strong KIF20A expression and 60 cases (40%) had a weak or negative KIF20A expression ([Table 1](#t1-cmar-10-3433){ref-type="table"}). KIF20A was mostly positioned in the nucleus and cytoplasm of the ovarian cancer cells. The expression of KIF20A was low or absent in normal ovarian tissues. The intensity of KIF20A staining increases sequentially from clinical stage I to IV ([Figure 3A](#f3-cmar-10-3433){ref-type="fig"}). As shown in [Figure S2A--D](#SD1-cmar-10-3433){ref-type="supplementary-material"}, we conducted IHC staining in four histological types of EOC, including serous adenocarcinoma, mucoid adenocarcinoma, endometrial adenocarcinoma, and clear cell adenocarcinoma. Besides, the expression of KIF20A protein was stronger in recurrence group than in the nonrecurrence group ([Figure 3](#f3-cmar-10-3433){ref-type="fig"}). We noted positive KIF20A protein expression in 40% (10/25), 38.89% (7/18), 66.26% (55/83), and 88.89% (8/9) stage I, II, III, and IV tumors, respectively (*P*\<0.05, [Table 2](#t2-cmar-10-3433){ref-type="table"}). Quantitative IHC analysis suggested that mean optical density (MOD) value of KIF20A was obviously correlated with FIGO stages ([Figure 3B](#f3-cmar-10-3433){ref-type="fig"}) and was higher in recurrence group than in nonrecurrence group ([Figure 3D](#f3-cmar-10-3433){ref-type="fig"}). Moreover, the chi-squared test and Fisher's exact test were performed to analyze the correlation between KIF20A expression and clinicopathological parameters ([Table 2](#t2-cmar-10-3433){ref-type="table"}). Spearman's correlation test indicated that the elevated expression correlated with FIGO stage (*P*=0.001), intraperitoneal metastasis (*P*=0.000), lymph node (LN) metastasis (*P*=0.002), vital status at last follow-up (*P*\<0.001), intraperitoneal recurrence (*P*=0.030), ascites with tumor cells (*P*\<0.001), and drug resistance (*P*=0.012). Additionally, patients with KIF20A protein level upregulation were experienced more tumor recurrence (*P*=0.005); therefore, the vital prognosis of these patients was poor. On the contrary, the correlations between KIF20A expression and age; histological type; intestinal metastasis; residual tumor size; differentiation grade; postoperative chemotherapy; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy (HIPEC); and serum CA125, CA199, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and β human choriogonadotropin (β-HCG) levels were not statistically significant ([Table 3](#t3-cmar-10-3433){ref-type="table"}). These results indicate that KIF20A has an important impact on ovarian cancer recurrence and progression.

High KIF20A expression was obviously related with poor prognosis in EOC
-----------------------------------------------------------------------

Survival analysis pointed that patients with KIF20A overexpression had a significantly shorter overall survival (OS) and disease-free survival than those with low KIF20A expression ([Figure 4A, B](#f4-cmar-10-3433){ref-type="fig"}, log-rank, *P*\<0.001). In the cohort, patients with elevated KIF20A expression had an obviously lower cumulative 5-year survival rate compared with those with low KIF20A expression (27.4% vs 84.0%, respectively; *P*\<0.05). We also examined the prognostic value of KIF20A expression in subgroups stratified by tumor recurrence ([Figure 4C](#f4-cmar-10-3433){ref-type="fig"}); intraperitoneal recurrence ([Figure 4D](#f4-cmar-10-3433){ref-type="fig"}); age ([Figure 4E, F](#f4-cmar-10-3433){ref-type="fig"}); intestinal metastasis ([Figure 4G](#f4-cmar-10-3433){ref-type="fig"}); ascites with tumor cells ([Figure 4H](#f4-cmar-10-3433){ref-type="fig"}); serum biomarker levels CA125 ([Figure 4I](#f4-cmar-10-3433){ref-type="fig"}); differentiation grade ([Figure 4J, K](#f4-cmar-10-3433){ref-type="fig"}); neoadjuvant chemotherapy ([Figure 4L, M](#f4-cmar-10-3433){ref-type="fig"}); postoperative chemotherapy ([Figure 4N](#f4-cmar-10-3433){ref-type="fig"}); FIGO stages ([Figure 4O, P](#f4-cmar-10-3433){ref-type="fig"}); Univariate Cox analysis showed that KIF20A protein level (*P*\<0.001), age (*P*=0.025), CA153 levels (*P*=0.003), CA199 levels (*P*=0.021), intraperitoneal metastasis (*P*\<0.001), intestinal metastasis (*P*\<0.001), ascites with tumor cells (*P*\<0.001), neoadjuvant chemotherapy (*P*=0.001), LN metastasis (*P*\<0.001), and tumor recurrence (*P*\<0.001) could serve as important prognostic factors ([Table 4](#t4-cmar-10-3433){ref-type="table"}). Furthermore, multivariate Cox regression analysis showed that only KIF20A protein expression level (*P*=0.017) and tumor recurrence (*P*=0.009) were statistically significant ([Table 4](#t4-cmar-10-3433){ref-type="table"}).

Overexpression of KIF20A facilitates the invasion and metastasis abilities of EOC cells
---------------------------------------------------------------------------------------

To further explore the function of KIF20A in the invasion and metastasis of EOC, we transiently transfected KIF20A cDNA and KIF20A-siRNA to A2780 cells and SKOV3 cells for 24 hours. Western blot assay was used to evaluate the efficiency ([Figure S1](#SD1-cmar-10-3433){ref-type="supplementary-material"}). As shown in [Figure 5A--C](#f5-cmar-10-3433){ref-type="fig"}, overexpression of KIF20A enhanced invasion ability of A2780 and SKOV3 cells, whereas silence of KIF20A remarkably reduced the invasive cell numbers. Furthermore, by using the wound healing assay, we found that the KIF20A-transduced EOC cells exhibit an increase in migration ability, while the KIF20A-silenced cells showed an inhibition in their migration ability ([Figure 5D, E](#f5-cmar-10-3433){ref-type="fig"}). These data show that overexpression of KIF20A facilitates EOC cells' invasion and migration abilities compared with vector control cells.

KIF20A confers resistance to cisplatin in EOC cells
---------------------------------------------------

To further verify that KIF20A mediates ovarian cancer cells' chemoresistance, MTT/IC50 assay and Annexin V-FITC/PI assay were performed on the indicated cells. MTT/IC50 assay indicated that the IC50 value for cisplatin was obviously raised in KIF20A-overexpression ovarian cancer cells, while it was decreased in KIF20A-silenced cells ([Figure 6A, B](#f6-cmar-10-3433){ref-type="fig"}). Consistently, we also found that the proportion of apoptotic cells in KIF20A-overexpression group treated with cisplatin was much lower compared with the control group, yet much higher in the KIF20A-silenced group ([Figure 6C](#f6-cmar-10-3433){ref-type="fig"}). Collectively, these results strongly suggest that KIF20A confers chemoresistance in EOC cells.

Discussion
==========

Similar to our study, recent studies have reported that KIF20A is upregulated in several cancers.[@b11-cmar-10-3433]--[@b15-cmar-10-3433] Besides, significant evidence indicated that high expression of KIF20A promotes cell metastasis and proliferation in various types of cancers, indicating that overexpression of KIF20A is related to tumor progression.[@b14-cmar-10-3433],[@b15-cmar-10-3433],[@b17-cmar-10-3433],[@b18-cmar-10-3433]

As far as we know, this is the first exploration that KIF20A overexpression is closely related to unfavorable prognosis and clinical characteristics, especially tumor recurrence, in EOC. We found that the upregulation of KIF20A occurred at both mRNA and protein levels in EOC tissues in comparison with normal ovarian tissues. High KIF20A expression was closely correlated with FIGO stage, intraperitoneal metastasis, LN metastasis, vital status at last follow-up, tumor recurrence, intraperitoneal recurrence, ascites with tumor cells, and drug resistance. Patients with upregulated KIF20A expression were more likely to experience tumor recurrence during treatment, which is an important cause of poor prognosis of EOC. Univariate and multivariate regression analyses revealed that KIF20A expression can serve as an independent prognostic marker in EOC. Our results show that high KIF20A protein expression correlates with tumor progression and may be viewed as a valuable prognostic factor of clinical outcomes in EOC.

There are many factors related to this poor prognosis in ovarian cancer, of which an important one is tumor progression. Drug resistance is an important reason for tumor progression. In most cases, ovarian cancer is one of the most treatable solid tumors at the early stage of treatment. However, ovarian cancer cells may develop drug chemoresistance during treatment, which causes further treatments to be ineffective and induce tumor progression. Ultimately, there is minimal improvement in OS of ovarian cancer patients during the past 30 years.[@b19-cmar-10-3433] Even in the era of precision treatment, predicting the chemotherapy response and tumor progression of patients with EOC is extremely difficult. A platinum-based drug and a taxane were regarded as the first-line chemotherapy for advanced EOC patients.[@b20-cmar-10-3433] Paclitaxel belongs to the family of antimitotic anticancer agents and blocks mitosis by stabilizing microtubules, leading to the blockage of cell division and therefore cell survival.[@b16-cmar-10-3433] KIF20A is a microtubule-associated motor protein, and it plays the role of intracellular organelle transport and cell division.[@b17-cmar-10-3433] Paclitaxel primarily disturbs mitotic spindle dynamics and triggers the mitotic checkpoint to induce extended G2/M arrest that can incur cell death via the intrinsic (mitochondrial) apoptotic pathway.[@b19-cmar-10-3433] It is not difficult to surmise that high KIF20A expression correlates with chemoresistance. Additionally, in breast cancer, fork-head box M1-induced upregulation of KIF20A at transcriptional level confers drug resistance.[@b20-cmar-10-3433],[@b22-cmar-10-3433] Consistent with these reports, our findings provided evidence that overexpression of KIF20A strongly reduced the proportion of apoptosis cells, while knockdown of KIF20A obviously increased apoptosis cells compared with the control cells. Moreover, there are numerous mechanisms of drug resistance, involving the elevation of efflux mediated by P-glycoprotein coded by the ATP binding cassette subfamily B member 1 (*MDR1*/*ABCB1*) gene, spindle assembly checkpoint defects, mitotic slippage, activation of prosurvival signaling, and apoptosis evasion by modulating the activity of p53 and BCL2 family proteins.[@b21-cmar-10-3433] However, the precise mechanisms by which KIF20A affects chemoresistance require further investigation.

From the intraperitoneal metastasis subgroup data, KIF20A expression was nearly three times that in the nonintraperitoneal metastasis subgroup. Intraperitoneal metastasis may be another independent prognostic factor associated with poorer outcomes in EOC.[@b20-cmar-10-3433] In the majority of ovarian cancer cases, patients are always at an advanced stage, in which metastatic disease is already present, and detected, thus resulting in unfavorable prognosis. Unlike most solid tumors, EOC metastasis often occurs through the shedding of cancer cells from the ovarian tumor directly into the peritoneal cavity.[@b23-cmar-10-3433] In addition, intraperitoneal metastasis may have an important role in the clinical staging of EOC according to FIGO 2014. Therefore, it is important to detect intraperitoneal metastasis at the early stages in EOC.[@b24-cmar-10-3433] However, to date, there is lack of sensitive molecular bio-markers for detecting early intraperitoneal metastasis.[@b28-cmar-10-3433] Our findings show that KIF20A expression correlates strongly with intraperitoneal metastasis in EOC. Additionally, Cox regression analyses showed that intraperitoneal metastasis is an important factor that shortens the OS of EOC. KIF20A expression in noncancerous ovarian tissue and primary ovarian cancer without intraperitoneal metastasis group was very low; however, ovarian cancer with intraperitoneal metastasis had remarkably high KIF20A expression. This suggests that KIF20A overexpression is related to intraperitoneal metastasis and poor outcome in EOC. Therefore, KIF20A can been seen as a biomarker for detecting intraperitoneal metastasis at the early stages of EOC and may contribute to improving survival of EOC patients.[@b24-cmar-10-3433],[@b28-cmar-10-3433]

LN metastasis is another valuable prognostic factor of EOC[@b25-cmar-10-3433] and is also an important factor for doctors to select suitable treatments. Clinically, the 5-year survival rate of EOC is \>90% when the tumor is limited to the ovary; however, it decreases to only 30% when the metastasis has happened.[@b1-cmar-10-3433] Patients with negative LNs have longer OS than patients with positive LNs.[@b26-cmar-10-3433] Furthermore, detecting LN metastasis preoperatively can help doctors to determine whether there is a need for LN dissection. It contributes to the reduction of postoperative complications and to improving patients' quality of life.[@b27-cmar-10-3433],[@b29-cmar-10-3433] In our study, using univariate Cox regression analyses, we found that LN metastasis was a significant prognostic factor (*P*\<0.001; [Table 4](#t4-cmar-10-3433){ref-type="table"}). Therefore, detecting LN metastasis at the early stages may improve OS of EOC patients. However, currently, there are no markers for predicting LN status with high sensitivity and specificity.[@b30-cmar-10-3433] Our findings show an obvious correlation between KIF20A overexpression with LN metastasis. Therefore, we suggest that KIF20A may be considered as a valuable biomarker for detecting LN metastasis in ovarian cancer. Thus, during further studies, a larger EOC cohort is needed to verify our results on LN metastasis, and the mechanism of KIF20A promoting LN metastasis of EOC should also be investigated.

Also, wound healing assay and transwell assay were used to evaluate the ability of migration and invasion of EOC cells. Our research shows that upregulation of KIF20A strongly enhanced migration and invasion abilities in EOC cells, but KIF20A-silenced cells obviously reduced migration and invasion. Angiogenesis is an important factor in the growth and invasion of malignant tumor. Vascular endothelial growth factor A (VEGF-A) belonging to VEGF family, plays an important role in angiogenesis, which is necessary for cell invasion and migration.[@b31-cmar-10-3433],[@b32-cmar-10-3433] The association between upregulation of VEGF-A and invasion has been reported in several cancers, including ovarian cancer.[@b33-cmar-10-3433]--[@b36-cmar-10-3433] Exertier et al reported that KIF20A/MKLP2 combined with VEGF-A stimulates angiogenesis in vivo, and mitosis-independent vascular outgrowth was potently impaired by KIF20A inhibitor.[@b37-cmar-10-3433] Collectively, we suggest that overexpression of KIF20A may enhance the ability of migration and invasion by regulating VEGF. Nevertheless, we should conduct further exploration to validate it.

Cancer immunotherapy has emerged recently as a promising means of treating cancer; consequently, researching and developing peptide vaccines targeting tumor-specific antigens is important.[@b38-cmar-10-3433],[@b39-cmar-10-3433] Several methods of EOC immunotherapy have been studied at present.[@b39-cmar-10-3433] Moreover, antitumor immune responses by the immune system has been considered as a promising cancer treatment. Previous studies have shown that KIF20A has been used in immunotherapy for various cancers. Asahara et al performed an immunotherapy treatment that utilized KIF20A-66 cancer vaccine reagent, a human leukocyte antigen-A24-restricted epitope peptide obtained from KIF20A, which is significantly transactivated in pancreatic cancer, to treat pancreatic cancer. Patients who were vaccinated with KIF20A-66 had a better clinical outcome than the control group, and further clinical research using this peptide also achieved high potential benefit for patients in advanced stage of pancreatic cancer.[@b38-cmar-10-3433] In immunotherapy of lung cancer and cholangiocellular carcinoma, a Phase I/II clinical trial is currently being carried out using KIF20A-derived short peptides.[@b40-cmar-10-3433] Excitingly, Tomita et al reported that KIF20A long peptides (LP) stimulate KIF20A-specific cytotoxic T lymphocytes in vitro and in vivo.[@b40-cmar-10-3433] KIF20A-specific T-helper type 1 (TH1) cell responses were investigated in head and neck cancer patients and then they received this immunotherapy (8/16, 50%). This finding reveals that the induction of KIF20A-specific TH1 cells in response to KIF20A-LP vaccination may promote the clinical response to chemotherapy or other standard therapies, such as radiotherapy or surgery.[@b41-cmar-10-3433]--[@b43-cmar-10-3433] Therefore, based on these previous studies, we believe that conducting research on KIF20A peptide-based immunotherapy of EOC is worthwhile. KIF20A may be a potential cancer therapeutic target to improve survival in EOC.

There are some limitations in our research. Firstly, our work was a retrospective study. Secondly, we performed migration, invasion, and chemoresistance related experiments in vitro, while we lacked some experiments in vivo to confirm our idea. But, in future experiments we will further conduct related in vivo experiments to verify our hypothesis and investigate the molecule mechanism.

Conclusions
===========

In conclusion, our study provides convincing data that KIF20A is overexpressed in the majority of EOC tissues, and KIF20A expression could serve as an independent prognostic indicator for EOC patients. However, further examination of the molecular mechanisms behind the KIF20A-mediated potential tumorigenic effects in ovarian cancer is needed.

Supplementary materials
=======================

###### 

(**A**) Immunohistochemical detection of KiF20a protein in 10 pairs of matched ovarian cancer tissues (×400). (**B**) The silence efficiency and overexpression efficiency of endogenous KIF20A expression on protein levels were detected by Western blotting analysis.

###### 

Representative immunohistochemical images of four histological types of epithelial ovarian cancer tissues (×200).

**Notes:** (**A**) Serous adenocarcinoma, (**B**) mucoid adenocarcinoma, (**C**) endometrial adenocarcinoma, and (**D**) clear cell carcinoma.
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![KIF20A mRNA and protein were overexpressed in EOC cell lines.\
**Notes:** (**A**, **B**) Expression of KIF20A mRNA and protein in EOC cell lines (COV644, COV362, OV90, SKOV3, TOV112D, OVCAR4, A2780, COV434, TOV21G) and normal ovarian epithelial cell (HOSEpiC) by real-time PCR (**A**) and Western blotting (**B**). Expression levels were normalized to GAPDH expression. Error bars represent standard deviation (SD) of the mean calculated from three parallel experiments. ^\*^*P*\<0.05.\
**Abbreviations:** EOC, epithelial ovarian cancer; PCR, polymerase chain reaction.](cmar-10-3433Fig1){#f1-cmar-10-3433}

![Overexpression of KIF20A mRNA and protein in EOC specimens.\
**Notes:** (**A**) The average T/ANT ratios of KIF20A mRNA expression in the ovarian cancer (T) and adjacent noncancerous tissue sections were quantified using real-time PCR and normalized against GAPDH. Error bars represent standard deviation (SD) of the mean calculated from three parallel experiments. (**B**, **C**) Western blotting analyses of KIF20A expression in ten pairs of ovarian cancer tissues (T) and ANT. GAPDH was used as the loading control. (**D**) Immunohistochemical detection of KIF20A protein in ten pairs of matched ovarian cancer tissues. ^\*^*P*\<0.05.\
**Abbreviations:** ANT, adjacent noncancerous tissue; EOC, epithelial ovarian cancer; PCR, polymerase chain reaction.](cmar-10-3433Fig2){#f2-cmar-10-3433}

![KIF20A protein expression in paraffin-embedded tissues.\
**Notes:** (**A**) Representative images from immunohistochemical staining of KIF20A protein expression in ovarian cancer tissues at four clinical stages. (**B**) The average MOD of KIF20A staining in four clinical stages groups ^\*^*P*\<0.05 (**C**). Representative images of KIF20A expression in recurrence group and nonrecurrence group. (**D**) The statistical analyses of the average MOD of KIF20A staining in the recurrence group and nonrecurrence group ^\*^*P*\<0.05.\
**Abbreviation:** MOD, mean optical density.](cmar-10-3433Fig3){#f3-cmar-10-3433}

![Kaplan--Meier curves of univariate analysis data (log-rank test).\
**Notes:** Survival curves for the patients in select patient subgroups (log-rank test). The OS and DFS of the patients with low KIF20A expression vs high KIF20A expression (**A, B**). OS rates for patients with tumor recurrence (**C**), intraperitoneal recurrence (**D**), aged ≤53 years (**E**), aged \>53 years (**F**), intestinal metastasis (**G**), ascites with tumor cells (**H**), CA125 \>35 U/mL (**I**) at differentiation grades 1 and 2 (**J**), at differentiation grade 3 (**K**), without neoadjuvant chemotherapy (**L**), with neoadjuvant chemotherapy (**M**), postoperative chemotherapy (**N**), at stages 1, 2 (**O**), and at stages 3, 4 (**P**).\
**Abbreviations:** DFS, disease-free survival; OS, overall survival.](cmar-10-3433Fig4){#f4-cmar-10-3433}

![Upregulation of KIF20A enhances the invasive and metastatic abilities of EOC cells, while knockdown of KIF20A represses the invasive and metastatic abilities.\
**Notes:** (**A--C**) The invasive and metastatic abilities of EOC cells were assessed by transwell assay. Each bar represents the mean±SD of three parallel experiments. (**D, E**) Representative images of wound healing assay; mobility of cells was evaluated by wound closure (%) at 0, 12, 24 hours ^\*^*P*\<0.05.\
**Abbreviation:** EOC, epithelial ovarian cancer.](cmar-10-3433Fig5){#f5-cmar-10-3433}

![KIF20A confers cisplatin resistance in EOC cells.\
**Notes:** (**A, B**) MTT/IC50 assay evaluates the viability of KIF20A-overexpressed and KIF20A-silenced EOC cells after cisplatin treatment for 48 hours. (**C**) Apoptosis assay analyzes the percentage of apoptosis cells for KIF20A-overexpressed and KIF20A-silenced EOC cells after cisplatin treatment (5 µM) for 24 hours ^\*^*P*\<0.05.\
**Abbreviation:** EOC, epithelial ovarian cancer.](cmar-10-3433Fig6){#f6-cmar-10-3433}

###### 

Clinicopathological characteristics and tumor expression of KIF20A in epithelial ovarian cancer

  Characteristic                       Cases, n (%)
  ------------------------------------ --------------
  **Age (years)**                      
  ≤53                                  81 (54.0)
  \>53                                 69 (46.0)
  **FIGO stage**                       
  I                                    25 (18.5)
  II                                   18 (13.3)
  III                                  83 (61.5)
  IV                                   9 (6.7)
  **Histological type**                
  Serous adenocarcinoma                119 (80.4)
  Mucoid adenocarcinoma                24 (16.2)
  Endometrial adenocarcinoma           3 (2.0)
  Clear cell carcinoma                 2 (1.4)
  **Lymph node metastasis**            
  Absent                               71 (56.3)
  Present                              55 (43.7)
  **Intraperitoneal metastasis**       
  No                                   56 (37.3)
  Yes                                  94 (62.7)
  **Intestinal metastasis**            
  No                                   68 (48.9)
  Yes                                  71 (51.1)
  **KIF20A expression**                
  Low or none                          60 (40.0)
  High                                 90 (60.0)
  **Vital status at last follow-up**   
  Alive                                69 (46.0)
  Dead                                 81 (54.0)
  **Tumor recurrence**                 
  No                                   60 (40.3)
  Yes                                  89 (59.7)
  **Intraperitoneal recurrence**       
  No                                   69 (69.7)
  Yes                                  30 (30.3)
  **Distant recurrence**               
  No                                   35 (60.3)
  Yes                                  23 (39.7)
  **Residual tumor size (cm)**         
  ≤1                                   98 (76.0)
  \>1                                  31 (24.0)
  **Differentiation grade**            
  G1/G2                                64 (50.8)
  G3                                   62 (49.2)
  **Neoadjuvant chemotherapy**         
  No                                   113 (75.3)
  Yes                                  37 (24.7)
  **Postoperative chemotherapy**       
  No                                   7 (4.7)
  Yes                                  143 (95.3)
  **HIPEC**                            
  No                                   108 (78.3)
  Yes                                  30 (21.7)
  **Ascites with tumor cells**         
  No                                   44 (44.9)
  Yes                                  54 (55.1)
  **Cytoreductive surgery**            
  No                                   26 (17.3)
  Yes                                  124 (82.7)
  **Drug resistance**                  
  No                                   30 (52.6)
  Yes                                  27 (47.4)
  **CA125 (U/mL)**                     
  ≤35                                  7 (5.2)
  \>35                                 127 (94.8)
  **CA199 (U/mL)**                     
  ≤35                                  93 (69.4)
  \>35                                 41 (30.6)
  **CA153 (U/mL)**                     
  ≤25                                  27 (22.9)
  \>25                                 91 (77.1)
  **NSE (U/mL)**                       
  ≤15.2                                31 (36.9)
  \>15.2                               53 (63.1)
  **CEA (U/mL)**                       
  ≤5.0                                 90 (79.6)
  \>5.0                                23 (20.4)
  β-**HCG (U/mL)**                     
  ≤3.0                                 54 (80.6)
  \>3.0                                13 (19.4)

**Abbreviations:** β-HCG, β human choriogonadotropin; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics stage; HIPEC, hyperthermic intraperitoneal chemotherapy; NSE, neuron-specific enolase.

###### 

Correlation between KIF20A expression and the clinicopathological features of epithelial ovarian cancer

  Characteristic                                                    Total   KIF20A expression   Chi- square test *P*-value   Fisher's exact test *P*-value   
  ------------------------------------ ---------------------------- ------- ------------------- ---------------------------- ------------------------------- ---------
  **Age (years)**                      ≤53                          81      33 (22.0)           48 (32.0)                    0.841                           0.869
                                       \>53                         69      27 (18.0)           42 (28)                                                      
  **Histological type**                Serous adenocarcinoma        119     46 (31.1)           73 (49.3)                    0.114                           --
                                       Mucoid adenocarcinoma        24      10 (6.7)            14 (9.5)                                                     
                                       Endometrial adenocarcinoma   3       3 (2.0)             0 (0)                                                        
                                       Clear cell carcinoma         2       0 (0)               2 (1.3)                                                      
  **FIGO stage**                       I                            25      15 (11.1)           10 (6.8)                     0.008                           --
                                       II                           18      11 (8.1)            7 (5.2)                                                      
                                       III                          83      28 (20.7)           55 (40.7)                                                    
                                       IV                           9       1 (0.7)             8 (5.9)                                                      
  **Lymph node metastasis**            Absent                       71      37 (29.4)           34 (27.0)                    0.002                           0.003
                                       Present                      55      14 (11.1)           41 (32.5)                                                    
  **Intraperitoneal metastasis**       No                           56      35 (23.3)           21 (14.0)                    \<0.001                         \<0.001
                                       Yes                          94      25 (16.7)           69 (46.0)                                                    
  **Intestinal metastasis**            No                           68      30 (21.6)           38 (27.3)                    0.283                           0.303
                                       Yes                          71      25 (18.0)           46 (33.1)                                                    
  **Vital status at last follow-up**   Alive                        69      45 (30.0)           24 (16.0)                    \<0.001                         \<0.001
                                       Dead                         81      15 (10.0)           66 (44.0)                                                    
  **Intraperitoneal recurrence**       No                           69      37 (37.3)           32 (32.3)                    0.030                           0.048
                                       Yes                          30      9 (9.1)             21 (21.2)                                                    
  **Distant recurrence**               No                           35      11 (19.0)           24 (41.4)                    0.546                           0.583
                                       Yes                          23      9 (15.5)            14 (24.1)                                                    
  **Tumor recurrence**                 No                           60      32 (21.5)           28 (18.8)                    0.005                           0.006
                                       Yes                          89      27 (18.8)           62 (29.0)                                                    
  **Residual tumor size (cm)**         ≤1                           98      42 (32.6)           56 (43.4)                    0.467                           0.534
                                       \>1                          31      11 (8.5)            20 (15.5)                                                    
  **Differentiation grade**            G1/G2                        64      25 (19.8)           39 (31.0)                    0.743                           0.856
                                       G3                           62      26 (20.6)           36 (28.6)                                                    
  **Neoadjuvant chemotherapy**         No                           113     50 (33.3)           63 (42.0)                    0.063                           0.082
                                       Yes                          37      10 (6.7)            27 (18.0)                                                    
  **Postoperative chemotherapy**       No                           7       3 (2.0)             4 (2.7)                      0.724                           1.000
                                       Yes                          143     58 (38.7)           85 (56.7)                                                    
  **Drug resistance**                  No                           30      15 (26.3)           15 (26.3)                    0.013                           0.025
                                       Yes                          27      5 (8.8)             22 (38.6)                                                    
  **HIPEC**                            No                           108     46 (33.3)           62 (44.9)                    0.213                           0.292
                                       Yes                          30      9 (6.5)             21 (15.2)                                                    
  **Ascites with tumor cells**         No                           44      27 (27.6)           14 (14.3)                    \<0.001                         \<0.001
                                       Yes                          54      13 (13.3)           41 (41.8)                                                    
  **Cytoreductive surgery**            No                           26      10 (6.7)            16 (10.7)                    0.860                           1.000
                                       Yes                          124     50 (33.3)           74 (49.3)                                                    
  **CA125 (U/mL)**                     ≤35                          7       2 (1.5)             5 (3.7)                      0.568                           0.706
                                       \>35                         127     50 (37.3)           77 (57.5)                                                    
  **CA199 (U/mL)**                     ≤35                          93      33 (24.6)           60 (44.8)                    0.147                           0.180
                                       \>35                         41      20 (14.9)           21 (15.7)                                                    
  **CA153 (U/mL)**                     ≤25                          27      13 (11.0)           14 (11.9)                    0.223                           0.262
                                       \>25                         91      32 (27.1)           59 (50.0)                                                    
  **NSE (U/mL)**                       ≤15.2                        31      10 (11.9)           21 (25.0)                    0.313                           0.361
                                       \>15.2                       53      23 (27.4)           30 (35.7)                                                    
  **CEA (U/mL)**                       ≤5.0                         90      39 (34.5)           51 (45.1)                    0.132                           0.157
                                       \>5.0                        23      6 (5.3)             17 (15.0)                                                    
  β-**HCG (U/mL)**                     ≤3.0                         54      21 (31.3)           33 (49.3)                    0.977                           1.000
                                       \>3.0                        13      5 (7.5)             8 (11.9)                                                     

**Abbreviations:** β-HCG, β human choriogonadotropin; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics stage; HIPEC, hyperthermic intraperitoneal chemotherapy; NSE, neuron-specific enolase.

###### 

Correlation between KIF20A expression and the clinicopathological characteristics of epithelial ovarian cancer

  Variable                         KIF20A expression   
  -------------------------------- ------------------- ---------
  Age                              0.016               0.842
  Histological type                --0.54              0.518
  FIGO stage                       0.291               0.001
  Intraperitoneal metastasis       0.354               \<0.001
  Lymph node metastasis            0.269               0.002
  Intestinal metastasis            0.091               0.286
  Vital status at last follow-up   0.475               \<0.001
  Tumor recurrence                 0.231               0.005
  Intraperitoneal recurrence       0.218               0.030
  Distant recurrence               --0.079             0.554
  Residual tumor size (cm)         0.064               0.471
  Differentiation grade            --0.029             0.745
  Neoadjuvant chemotherapy         0.152               0.064
  Postoperative chemotherapy       --0.029             0.726
  HIPEC                            0.106               0.216
  Ascites with tumor cells         0.377               \<0.001
  Cytoreductive surgery            --0.014             0.861
  Drug resistance                  0.329               0.012
  CA125 (U/mL)                     --0.049             0.572
  CA199 (U/mL)                     --0.125             0.149
  CA153 (U/mL)                     0.112               0.226
  NSE (U/mL)                       --0.110             0.319
  CEA (U/mL)                       0.142               0.134
  β-HCG (U/mL)                     0.003               0.978

**Abbreviations:** β-HCG, β human choriogonadotropin; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics stage; HIPEC, hyperthermic intraperitoneal chemotherapy; NSE, neuron-specific enolase.

###### 

Cox regression univariate and multivariate analyses of prognostic factors in epithelial ovarian cancer

  Variable                           Patients (n)   Univariate analysis   Multivariate analysis                   
  ---------------------------------- -------------- --------------------- ----------------------- ------- ------- ---------------
  **KIF20A**                                                                                                      
  Low expression                     60             \<0.001               1.902 (0.293)           0.017   4.784   1.318--17.369
  High expression                    90                                                                           
  **Intraperitoneal metastasis**                                                                                  
  No                                 56             \<0.001               1.880 (0.329)           0.209   2.885   0.552--15.074
  Yes                                94                                                                           
  **Age (years)**                                                                                                 
  ≤53                                81             0.025                 0.503 (0.224)           0.582   0.804   0.369--1.751
  \>53                               69                                                                           
  **Intestinal metastasis**                                                                                       
  No                                 68             0.017                 0.566 (0.236)           0.35    0.686   0.312--1.512
  Yes                                71                                                                           
  **Neoadjuvant chemotherapy**                                                                                    
  No                                 113            0.001                 0.785 (0.253)           0.882   1.063   0.472--2.397
  Yes                                37                                                                           
  **CA153 (U/mL)**                                                                                                
  ≤25                                27             0.003                 1.300 (0.430)           0.122   2.92    0.75--11.372
  \>25                               91                                                                           
  **CA199 (U/mL)**                                                                                                
  ≤35                                93             0.021                 --0.655 (0.285)         0.828   1.104   0.452--2.694
  \>35                               41                                                                           
  **Ascites with tumor cells (+)**                                                                                
  No                                 44             0.001                 1.005 (0.311)           0.811   0.875   0.294--2.605
  Yes                                54                                                                           
  **Lymph node metastasis**                                                                                       
  No                                 71             \<0.001               0.923 (0.251)           0.484   1.357   0.578--3.188
  Yes                                55                                                                           
  **Tumor recurrence**                                                                                            
  No                                 60             \<0.001               1.585 (0.290)           0.009   6.961   1.614--30.019
  Yes                                89                                                                           

[^1]: These authors contributed equally to this work
